What Eli Lilly, Novo Nordisk earnings show about GLP-1 sales

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 39 sec. here
  • 6 min. at publisher
  • 📊 Quality Score:
  • News: 33%
  • Publisher: 63%

Eli Lilly And Company Nouvelles

Novo Nordisk,Anjalee Khemlani,Earnings Results

Recent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created...

discusses both companies' earnings results, with Eli Lilly seeing strong sales of its GLP-1 drugs Mounjaro and Zepbound. Khemlani also takes a look at some of the other pharmaceutical companies in the GLP-1 space.Another trending story that we are watching here in the health care space G LP one, a key driver of the broader health care space.This earning season, companies like Eli Lily and no, no showing the demand for weight loss treatments does remain strong.

Pfizer, however, has been slowing down its prospects decreasing as it ran into some trouble with its drug, the oral GP one that it is now in clinical trials with it still figuring out the dosing for its one daily and it had a that didn't have good tolerability.Meanwhile, Amgen, moving ahead with its once monthly potentially injectable, that's in phase two and going to be going to phase three trial soon.

After one of the most exciting games in United States men's basketball history, Kevin Durant was awake early in the morning. The late Kobe Bryant, who was Durant's teammate the 2012 London Olympics, used to discuss the Antoniette Costa Reveals She Underwent Brain Surgery: 'There Was a Risk That I Wouldn't Be Able to Sing Again'

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 47. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earningsShares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The...
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »